TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Zacks Research

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

TLSI has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of TriSalus Life Sciences in a report on Monday. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Canaccord Genuity Group boosted their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $11.00.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $7.30 on Tuesday. The company has a market capitalization of $364.71 million, a PE ratio of -3.61 and a beta of 0.43. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.70. The company’s 50 day moving average price is $5.46 and its two-hundred day moving average price is $5.06.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The company had revenue of $11.57 million for the quarter, compared to the consensus estimate of $11.76 million. On average, research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently modified their holdings of the business. AWM Investment Company Inc. purchased a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $6,812,000. Charles Schwab Investment Management Inc. bought a new position in TriSalus Life Sciences during the 1st quarter valued at approximately $55,000. Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences during the first quarter valued at $187,000. Connective Capital Management LLC boosted its holdings in TriSalus Life Sciences by 12.8% in the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock worth $179,000 after acquiring an additional 3,717 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth $29,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.